{"id":169497,"date":"2024-06-03T02:37:29","date_gmt":"2024-06-03T06:37:29","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/nanobiotix-announces-new-data-showing-disease-control-and-tumor-response-in-patients-treated-with-rt-activated-nbtxr3-followed-by-anti-pd-1-for-2l\/"},"modified":"2024-08-18T11:48:30","modified_gmt":"2024-08-18T15:48:30","slug":"nanobiotix-announces-new-data-showing-disease-control-and-tumor-response-in-patients-treated-with-rt-activated-nbtxr3-followed-by-anti-pd-1-for-2l","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/nanobiotix-announces-new-data-showing-disease-control-and-tumor-response-in-patients-treated-with-rt-activated-nbtxr3-followed-by-anti-pd-1-for-2l.php","title":{"rendered":"Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+&#8230;"},"content":{"rendered":"<p><![CDATA[PARIS and CAMBRIDGE, Mass., June  02, 2024  (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO \u2013\u2013 NASDAQ: NBTX \u2013 the \u2018\u2018Company\u2019\u2019), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced new data from Study 1100, a US Phase 1 dose escalation and dose expansion study evaluating radiotherapy-activated NBTXR3 followed by anti-PD-1 immune checkpoint inhibitors (\u201cICIs\u201d) as a second-or-later line (\u201c2L+\u201d) therapy for patients with advanced solid and metastatic tumors. These data were presented by Study 1100 Coordinating Investigator Colette Shen, MD, PhD, at the 2024 Annual Meeting of the American Society for Clinical Oncology (\u201cASCO 2024\u201d).]]><\/p>\n<p>Read more:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/06\/02\/2891853\/0\/en\/Nanobiotix-Announces-New-Data-Showing-Disease-Control-and-Tumor-Response-in-Patients-Treated-With-RT-Activated-NBTXR3-Followed-By-anti-PD-1-For-2l-R-M-HNSCC-Na\u00efve-or-Resistant-to-P.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+...\">Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Read more: Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+... <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/nanobiotix-announces-new-data-showing-disease-control-and-tumor-response-in-patients-treated-with-rt-activated-nbtxr3-followed-by-anti-pd-1-for-2l.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-169497","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/169497"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=169497"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/169497\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=169497"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=169497"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=169497"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}